Novo Nordisk A/S Sponsored ADR (NVO)
What's Happening With Novo Nordisk Stock?
Novo Nordisk's stock has faced pressure following its Ozempic pill's failure in Alzheimer's disease trials, introducing new downside risks for the leader in weight loss medications. While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.
Novo Nordisk stock was rebounding in premarket trading Tuesday. It's a tale of two drug trials.
Novo Nordisk's Longshot Alzheimer's Trial Didn't Work, But It Is Still Worth Buying
Novo Nordisk A/S shares fell after phase 3 trials showed semaglutide did not slow Alzheimer's progression, though the trials were a longshot due to low optimism. NVO remains fundamentally strong, with robust revenue growth, solid margins, and a low P/E ratio, despite negative sentiment and competition from Eli Lilly. The company has multiple growth drivers, including an upcoming oral weight-loss pill, and maintains a significant global diabetes market share.
Novo Nordisk's weight-loss-drug trial provides rare good news in a rocky year
Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in development.
Novo Nordisk's obesity drug shows weight loss of up to 14.5% in mid-stage study
Novo Nordisk said on Tuesday its experimental obesity drug, amycretin, showed statistically significant weight loss of up to 14.5% at 36 weeks in patients with type 2 diabetes in a mid-stage study.
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.
Novo Nordisk (NVO) shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial.
Novo Nordisk shares slide after semaglutide Alzheimer's trial misses primary goal
Shares of Novo Nordisk (NYSE:NVO) fell sharply on Monday after the Danish pharmaceutical giant said a late-stage trial testing its diabetes and weight-loss drug semaglutide in Alzheimer's disease did not meet its main objective. The Phase III Evoke and Evoke+ trials, which enrolled nearly 3,800 patients with early signs of cognitive decline, showed no meaningful impact on disease progression, Novo Nordisk said.
Failing Drug Stock Suffers Another Blow on Drug Trial Data
Drug maker Novo Nordisk (NYSE:NVO) is sinking 7.8% to trade at $43.87 this morning, earlier hitting a more than four-year low of $43.37 after sharing disappointing trial data for its Alzheimer's drug, semaglutide.
Novo Nordisk stock slides as its Alzheimer's drug trials fail
Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding.
Novo Nordisk: Semaglutide's Success In Alzheimer's Was Unlikely
Novo Nordisk shares dropped after oral semaglutide failed in phase 3 Alzheimer's trials, ending hopes for this indication. The level of supportive evidence prior to this trial's readout was not high and this was not a surprising outcome. Street expectations for Alzheimer's were low, evidenced in a lack of a bump in revenue estimates for 2027 and beyond.
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
5 Things to Know Before the Stock Market Opens
Stock futures are pointing to a higher open for major indexes to kick off the holiday-shortened trading week; market participants are growing increasingly confident that the Federal Reserve will cut interest rates again next month; bitcoin regained some ground over the weekend after weeks of declines; U.S. officials are in Europe for tariff negotiations; and Ozempic-maker Novo Nordisk's U.S.-listed shares are sinking following the results of its latest drug trial. Here's what you need to know today.
